title: Omalizumab treatment in asthma-COPD overlap syndrome.
abstract: BACKGROUND
  Asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS) is a poorly understood disease with an increasing morbidity and mortality. Currently, the most effective treatment for ACOS is unknown and omalizumab for ACOS has not yet been reported.
  
  
  METHODS
  We report our experience with anti-IgE, omalizumab treatment on 3 patients with ACOS as a retrospective case study.
  
  
  RESULTS
  After 1 year of omalizumab treatment, patients experienced significantly lower rates of asthma exacerbation and hospitalization and better asthma control test results.
  
  
  CONCLUSIONS
  Our study shows that omalizumab may be an effective and safe therapy for patients with ACOS. However larger randomized trials are needed.
authors.affiliation: a Department of Internal Medicine, School of Medicine , Akdeniz University , Antalya , Turkey.
authors.forename: Tugba Songul
authors.initials: TS
authors.lastname: Tat
authors.affiliation: b Department of Pulmonary Medicine, School of Medicine , Akdeniz University , Antalya , Turkey.
authors.forename: Aykut
authors.initials: A
authors.lastname: Cilli
mesh_terms: D000328:Adult; D000368:Aged; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D008297:Male; D000069444:Omalizumab / Q000627:therapeutic use*; D029424:Pulmonary Disease, Chronic Obstructive / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D012129:Respiratory Function Tests; D013577:Syndrome; D016896:Treatment Outcome
chemical_list: D018927:Anti-Asthmatic Agents; D000069444:Omalizumab; D007073:Immunoglobulin E
keywords: ACOS; omalizumab